Rasagiline mesylate
Rasagiline mesylate
Rasagiline mesylate
| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-2315-50MG | Rasagiline mesylate | 50mg | $114.00 | |
| GBM-2315-250MG | Rasagiline mesylate | 250mg | $378.00 |
-
Description
MAO-B inhibitor; Neuroprotective
-
Specifications
Bioassays Specification Bio-Activity MAO-B inhibitor; Neuroprotective Chemical Name (1R)-2,3-Dihydro-N-2-propynyl-1H-inden-1-amine methanesulfonate Function / Pharmacology Potent, irreversible monoamine oxidase (MAO) inhibitor selective for MAO-B (IC50=4.43 nM) over MAO-A (IC50=412 nM).1 Parkinson’s disease therapeutic.2 Displays neuroprotective and neurorestorative properties in a Parkinson’s disease zebrafish model.3 Prevents -synuclein-induced dopaminergic neuronal death and rescues TrkB neurotrophic signaling.4 Enhances BDNF levels and is neuroprotective in Parkinson’s disease models.5 CAS# 161735-79-1 MW 267.34 Molecular Formula C12H13N • CH3SO3H Solubility Soluble in DMSO (up to 50 mg/ml), in Water (up to 50 mg/ml) or in Ethanol (up to 30 mg/ml) Supplied powder Storage as supplied -20°C Ship temp Ambient References 1) Youdim et al. (2001), Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B; Br. J. Pharmacol., 132 500 2) Cereda et al. (2017), Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case-control study; J. Neurol., 264 1254 3) Cronin and Grealy (2017), Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in Zebrafish 6-Hydroxydopamine Model of Parkinson’s Disease; Neuroscience, 367 34 4) Kang et al. (2017), TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson’s disease; Proc. Natl. Acad. Sci. USA, 114 10773 5) Ledreux et al. (2016), BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson’s disease; Brain Res., 1631 34 Antibody Specification Alternate Names TVP-1012; Azilect Protein Specification Purity >98% - Reviews
| Bioassays Specification | |
| Bio-Activity | MAO-B inhibitor; Neuroprotective |
| Chemical Name | (1R)-2,3-Dihydro-N-2-propynyl-1H-inden-1-amine methanesulfonate |
| Function / Pharmacology | Potent, irreversible monoamine oxidase (MAO) inhibitor selective for MAO-B (IC50=4.43 nM) over MAO-A (IC50=412 nM).1 Parkinson’s disease therapeutic.2 Displays neuroprotective and neurorestorative properties in a Parkinson’s disease zebrafish model.3 Prevents -synuclein-induced dopaminergic neuronal death and rescues TrkB neurotrophic signaling.4 Enhances BDNF levels and is neuroprotective in Parkinson’s disease models.5 |
| CAS# | 161735-79-1 |
| MW | 267.34 |
| Molecular Formula | C12H13N • CH3SO3H |
| Solubility | Soluble in DMSO (up to 50 mg/ml), in Water (up to 50 mg/ml) or in Ethanol (up to 30 mg/ml) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Youdim et al. (2001), Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B; Br. J. Pharmacol., 132 500 2) Cereda et al. (2017), Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case-control study; J. Neurol., 264 1254 3) Cronin and Grealy (2017), Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in Zebrafish 6-Hydroxydopamine Model of Parkinson’s Disease; Neuroscience, 367 34 4) Kang et al. (2017), TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson’s disease; Proc. Natl. Acad. Sci. USA, 114 10773 5) Ledreux et al. (2016), BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson’s disease; Brain Res., 1631 34 |
| Antibody Specification | |
| Alternate Names | TVP-1012; Azilect |
| Protein Specification | |
| Purity | >98% |